Our novel drug development pipeline was built through collaborations with top University researchers, industry leaders in novel delivery and manufacturing processes, and respected hospitals who care about their patients.
Our intellectual property portfolio of complex therapeutic mixtures currently includes: 6 issued US patents and 3 issued international patents as well as 17 US and 51 international patent-pending applications.
Animal Models used for establishing a Proof-of-Concept for our Optimized Therapeutic Mixtures for the treatment of Heart Failure.
FHI Clinical is a full-service contract research organization (CRO) with the global expertise, responsive approaches and proven solutions to manage complex clinical research around the world.
FHI has been selected as our CRO to help with our go-to-market strategy and draft clinical trial protocol for our COVID-19 related, anti-inflammatory